https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> Visualising the urethra for prostate radiotherapy planning https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49004 Wed 03 May 2023 12:17:09 AEST ]]> Real-time intrafraction prostate motion during linac based stereotactic radiotherapy with rectal displacement https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33946 Wed 02 Mar 2022 14:29:12 AEDT ]]> Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37462 Wed 02 Mar 2022 14:28:00 AEDT ]]> Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31943 P = 0.0012). Comparison (2) demonstrated a moderate difference with centre 2 plans producing slightly lower rectal doses (P = 0.013). Comparison (3) further demonstrated that Rectafix returned lower mean doses than SpaceOAR (P < 0.001). Although all dose levels were in favour of Rectafix, in absolute terms differences were small (2.6-9.0%). Conclusions: In well-selected prostate SBRT patients, Rectafix and SpaceOAR RDD's provide approximately equivalent rectal sparing.]]> Wed 02 Mar 2022 14:25:36 AEDT ]]> The first clinical implementation of a real-time six degree of freedom target tracking system during radiation therapy based on Kilovoltage Intrafraction Monitoring (KIM) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34638 Patient: A patient with prostate adenocarcinoma undergoing SBRT with 36.25 Gy, delivered in 5 fractions was enrolled in the study. 6DoF KIM technology: 2D positions of three implanted gold markers in each of the kV images (125 kV, 10 mA at 11 Hz) were acquired continuously during treatment. The 2D → 3D target position estimation was based on a probability distribution function. The 3D → 6DoF target rotation was calculated using an iterative closest point algorithm. The accuracy and precision of the KIM method was measured by comparing the real-time results with kV-MV triangulation. Results: Of the five treatment fractions, KIM was utilised successfully in four fractions. The intrafraction prostate motion resulted in three couch shifts in two fractions when the prostate motion exceeded the pre-set action threshold of 2 mm for more than 5 s. KIM translational accuracy and precision were 0.3 ± 0.6 mm, −0.2 ± 0.3 mm and 0.2 ± 0.7 mm in the Left-Right (LR), Superior-Inferior (SI) and Anterior-Posterior (AP) directions, respectively. The KIM rotational accuracy and precision were 0.8° ± 2.0°, −0.5° ± 3.3° and 0.3° ± 1.6° in the roll, pitch and yaw directions, respectively. Conclusion: This treatment represents, to the best of our knowledge, the first time a cancer patient’s tumour position and rotation have been monitored in real-time during treatment. The 6 DoF KIM system has sub-millimetre accuracy and precision in all three translational axes, and less than 1° accuracy and 4° precision in all three rotational axes.]]> Thu 24 Mar 2022 11:35:51 AEDT ]]> Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34741 Thu 17 Feb 2022 09:29:26 AEDT ]]> Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43577 Skin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.]]> Mon 26 Sep 2022 10:27:37 AEST ]]> Moderate hypofractionation for prostate cancer: A user's guide https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47485 Mon 23 Jan 2023 11:48:41 AEDT ]]>